<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
Novo Nordisk A/S (NYSE: NVO) has agreed to pay $100 million to settle a 2017 investor suit that alleged the Company failed to disclose that it was under the same pricing pressures as its competitors. Related Content: House Committee Questions Eli Lilly, Sanofi, Novo Nordisk On’ Unacceptably High’ Insulin Prices
...read full article on Benzinga
